The next step toward GMP-grade production of engineered immune cells
Files
Publication date
2016-02
Authors
Kierkels, Guido J J
Straetemans, Trudy
de Witte, Moniek
Kuball, J.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Removing less potent T cell subsets as well as poorly- or non-engineered cells can optimize effectiveness of engineered T cell therapy against cancer. We have recently described a novel, GMP-ready method for the purification of engineered immune cells that might further boost the clinical success of cancer immunotherapy.
Keywords
Adoptive immunotherapy, allogeneic stem cell transplantation, GMP grade production, T cell subsets, Taverne, Journal Article
Citation
Kierkels, G J J, Straetemans, T, de Witte, M A & Kuball, J 2016, 'The next step toward GMP-grade production of engineered immune cells', OncoImmunology, vol. 5, no. 2, e1076608. https://doi.org/10.1080/2162402X.2015.1076608